Emergency medicine research focuses on the rapid evaluation, stabilization, diagnosis, and treatment of urgent and life-threatening conditions. Our Emergency Medicine clinical trials may involve new medications, devices, or protocols designed to improve care during acute medical and traumatic events.

Common Conditions:
• Chest pain and other heart conditions
• Stroke symptoms
• Breathing emergencies
• Severe allergic reactions (anaphylaxis)
• Traumatic injuries (falls, fractures, head trauma)
• Abdominal pain emergencies

To learn more about participating in a clinical trial, please contact us at 

1-800-836-0388 or clinical.research@guthrie.org

 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06568939
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)
Department: Pulmonary
Diagnosis: Pulmonary (Lung)
Principal Investigator:

Hehn MD, Boyd

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT06878261
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Poulose MD, Joyson

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients with End-Stage Renal Disease
Department: Vascular Surgery
Diagnosis: Vascular Disease
Principal Investigator:

Hussain DO, Amber

Sponsors: W. L. Gore & Associates, Inc.
Title: A012103 OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Details (Identifier #): NCT05812807
Title: ASCENT A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Gilead Sciences
Details (Identifier #): NCT05633654
Showing 1-10 of 27 Results